IRCT20210519051345N5尚未招募未知
In vivo bioequivalence study of Quetiapine 100 mg tablet manufactured by Fatak Shimi Co. in comparison to innovator product
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 59 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart and Kidney)
- •Age (20-60)
排除标准
- •history of cardiovascular disease, history of liver and kidney disease,
- •alcohol and drug addiction
- •history of drug allergy
研究者
相似试验
招募中
不适用
Investigating the in vivo bioequivalence of Quetiapine 25 mg tabletIRCT20210519051345N21Tabriz University of Medical Sciences24
招募中
Unknown
Bioequivalence study of Quetiapine 25 mg tabletIRCT20210519051345N50Tabriz University of Medical Sciences24
已完成
1 期
Partially Replicate Bioequivalence Study of Quetiapine 25 mg in Healthy Volunteers Under Fasting ConditionBioequivalenceNCT05235230Future University in Egypt32
已完成
4 期
Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.HealthyNCT03317236Laboratorio Elea Phoenix S.A.24
尚未招募
1 期
Comparison of Efficacy of Quetiapine Alone versus Quetiapine plus Lamotrigine in the Treatment of Depressive episode of Bipolar I and II DisorderBipolar depressionTCTR20230712005university of health sciences, lahore166